MARKET

INVA

INVA

Innoviva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.62
-0.18
-1.53%
After Hours: 11.25 -0.37 -3.18% 17:48 02/25 EST
OPEN
11.83
PREV CLOSE
11.80
HIGH
11.96
LOW
11.51
VOLUME
629.98K
TURNOVER
--
52 WEEK HIGH
15.62
52 WEEK LOW
7.58
MARKET CAP
1.18B
P/E (TTM)
5.79
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: INNOVIVA, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Management's Discussion and...
Edgar Online - (EDG = 10Q, 10K) · 6h ago
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
LOS ALTOS, Calif., Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- LOS ALTOS, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage...
GlobeNewswire · 02/11 12:00
Innoviva: Q4 Earnings Insights
Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat the estimate of $0.40. Revenue of $90,476,000 rose by 19...
Benzinga · 02/03 22:44
Innoviva: Q4 Earnings Insights
Benzinga · 02/03 22:44
BRIEF-Innoviva Reports Qtrly Diluted Net Income Per Share Attributable To Innoviva Stockholders $0.48
reuters.com · 02/03 21:46
Innoviva reports Q4 results
Innoviva (INVA): Q4 GAAP EPS of $0.48.Revenue of $90.48M (+19.1% Y/Y)Press Release
Seekingalpha · 02/03 21:21
Innoviva 4Q EPS 48c >INVA
Innoviva 4Q EPS 48c >INVA
Dow Jones · 02/03 21:11
Innoviva 4Q Rev $90.5M >INVA
Innoviva 4Q Rev $90.5M >INVA
Dow Jones · 02/03 21:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INVA. Analyze the recent business situations of Innoviva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INVA stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 333
Institutional Holdings: 76.05M
% Owned: 75.01%
Shares Outstanding: 101.39M
TypeInstitutionsShares
Increased
65
2.18M
New
66
938.25K
Decreased
72
5.01M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Odysseas Kostas
Chief Executive Officer
Pavel Raifeld
Chief Financial Officer
Richard Brand
Chief Accounting Officer
Marianne Zhen
Independent Director
George Bickerstaff
Independent Director
Mark DiPaolo
Independent Director
Jules Haimovitz
Independent Director
Sarah Schlesinger
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/29/2015
Dividend USD 0.25
09/08/2015
--
Dividend USD 0.25
06/10/2015
02/23/2015
Dividend USD 0.25
03/10/2015
10/16/2014
Dividend USD 0.25
11/21/2014
08/06/2014
Dividend USD 0.25
08/26/2014
About INVA
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.